RecruitingNot Applicable

Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation

China154 participantsStarted 2024-06-03

Plain-language summary

The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years old
✓. Accept VA-ECMO or VV-ECMO
✓. the ECMO team believes that systemic anticoagulation is necessary and that APTT should be maintained at 40-60s.
✓. sign the informed consent form

Exclusion criteria

✕. previous history of allergy to heparin or bivalirudin
✕. previous diagnosis of heparin-induced thrombocytopenia.
✕. the pre-random ECMO assistance time is more than 48 hours.
✕. pregnant female
✕. have participated in this study before.
✕. the researchers believe that there are other factors that are not suitable to participate in this study.

What they're measuring

thrombotic complications

Timeframe: Within seven days after starting anticoagulant therapy

bleeding complications

Timeframe: Within seven days after starting anticoagulant therapy

Trial details

NCT IDNCT06275555

SponsorXiaotong Hou

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

Contact for this trial

Xiaotong Hou, MD

010-64456631 xt.hou@ccmu.edu.cn

View on ClinicalTrials.gov More Extracorporeal Membrane Oxygenation Complication trials